•  23
    Up till now, China has not enacted any legal mechanisms governing certification or supervision for ethics committees. This article analyses deficiencies in the protection of subjects in clinical drug trials under China’s current laws and regulations; it emphasizes that investigators, as practitioners who have direct contact with subjects, play significant roles in protecting and safeguarding subjects’ rights and interests. The paper compares the status quo in China in this area to that of other …Read more
  •  4
    Survival and Functionality of hESC-Derived Retinal Pigment Epithelium Cells Cultured as a Monolayer on Polymer Substrates Transplanted in RCS Rats
    with B. B. Thomas, D. Zhu, P. B. Thomas, Y. Hu, H. Nazari, F. Stefanini, P. Falabella, D. O. Clegg, D. R. Hinton, and M. S. Humayun
  •  2
    Stem cell based therapies for age-related macular degeneration: The promises and the challenges
    with H. Nazari, D. Zhu, G. J. Chader, P. Falabella, F. Stefanini, T. Rowland, D. O. Clegg, A. H. Kashani, D. R. Hinton, and M. S. Humayun
    © 2015 Elsevier Ltd.Age-related macular degeneration is the leading cause of blindness among the elderly in developed countries. AMD is classified as either neovascular or non-neovascular. Cumulative damage to the retinal pigment epithelium, Bruch's membrane, and choriocapillaris leads to dysfunction and loss of RPE cells. This causes degeneration of the overlying photoreceptors and consequential vision loss in advanced NNV-AMD. In NV-AMD, abnormal growth of capillaries under the retina and RPE,…Read more
  •  2
    Targeted genome editing across species using ZFNs and TALENs
    with A. J. Wood, T. W. Lo, B. Zeitler, C. S. Pickle, E. J. Ralston, A. H. Lee, R. Amora, J. C. Miller, E. Leung, X. Meng, E. J. Rebar, Gregory P. D., F. D. Urnov, and B. J. Meyer
  •  1
    A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection
    with W. Deng, B. G. Gowen, L. Wang, S. Lau, A. Iannello, J. Xu, T. L. Rovis, N. Xiong, and D. H. Raulet
    Immune cells, including natural killer cells, recognize transformed cells and eliminate them in a process termed immunosurveillance. It is thought that tumor cells evade immunosurveillance by shedding membrane ligands that bind to the NKG2D-activating receptor on NK cells and/or Tcells, and desensitize these cells. In contrast, we show that in mice, a shed form of MULT1, a high-affinity NKG2D ligand, causes NK cell activation and tumor rejection. Recombinant soluble MULT1 stimulated tumor reject…Read more
  •  3
    Cytokine therapy reverses NK cell anergy in MHC-deficient tumors
    with M. Ardolino, C. S. Azimi, A. Iannello, T. N. Trevino, L. Horan, W. Deng, A. M. Ring, S. Fischer, K. C. Garcia, and D. H. Raulet
    Various cytokines have been evaluated as potential anticancer drugs; however, most cytokine trials have shown relatively low efficacy. Here, we found that treatments with IL-12 and IL-18 or with a mutant form of IL-2 provided substantial therapeutic benefit for mice specifically bearing MHC class I-deficient tumors, but these treatments were ineffective for mice with matched MHC class I+ tumors. Cytokine efficacy was linked to the reversal of the anergic state of NK cells that specifically occur…Read more
  • Nuclear envelope protein MAN1 regulates clock through BMAL1
    with S. T. Lin, X. Lin, L. C. H. Zhang, V. E. L. Garcia, C. W. Tsai, L. Ptáček, and Y. H. Fu
    Copyright © 2014, Lin et al.Circadian clocks serve as internal pacemakers that influence many basic homeostatic processes; consequently, the expression and function of their components are tightly regulated by intricate networks of feedback loops that fine-tune circadian processes. Our knowledge of these components and pathways is far from exhaustive. In recent decades, the nuclear envelope has emerged as a global gene regulatory machine, although its role in circadian regulation has not been ex…Read more